JP2002514573A - 能動的なワクチン接種のための組成物および方法 - Google Patents
能動的なワクチン接種のための組成物および方法Info
- Publication number
- JP2002514573A JP2002514573A JP2000547851A JP2000547851A JP2002514573A JP 2002514573 A JP2002514573 A JP 2002514573A JP 2000547851 A JP2000547851 A JP 2000547851A JP 2000547851 A JP2000547851 A JP 2000547851A JP 2002514573 A JP2002514573 A JP 2002514573A
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- transmembrane protein
- interleukin
- protein
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 title claims description 24
- 238000002255 vaccination Methods 0.000 title claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract description 51
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract description 51
- 210000004027 cell Anatomy 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
- 229960005486 vaccine Drugs 0.000 claims abstract description 30
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 29
- 102000035160 transmembrane proteins Human genes 0.000 claims abstract description 27
- 108091005703 transmembrane proteins Proteins 0.000 claims abstract description 27
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 19
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 19
- 230000002163 immunogen Effects 0.000 claims abstract description 18
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 12
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 12
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract description 10
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract description 10
- 108091008605 VEGF receptors Proteins 0.000 claims abstract description 9
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims abstract description 9
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims abstract description 6
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims abstract description 6
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims abstract description 6
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims abstract description 6
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims abstract description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims abstract description 4
- 239000002671 adjuvant Substances 0.000 claims description 25
- 108010078791 Carrier Proteins Proteins 0.000 claims description 15
- 102000014914 Carrier Proteins Human genes 0.000 claims description 15
- -1 Her2-neu Proteins 0.000 claims description 5
- 108060003552 hemocyanin Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 19
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 230000000890 antigenic effect Effects 0.000 abstract description 12
- 238000013459 approach Methods 0.000 abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 230000008901 benefit Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000003211 malignant effect Effects 0.000 abstract description 5
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 abstract description 4
- 229940124292 CD20 monoclonal antibody Drugs 0.000 abstract description 3
- 101150029707 ERBB2 gene Proteins 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 2
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000009169 immunotherapy Methods 0.000 abstract description 2
- 230000000638 stimulation Effects 0.000 abstract description 2
- 206010048723 Multiple-drug resistance Diseases 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 6
- 239000000562 conjugate Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000863 peptide conjugate Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000009131 signaling function Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000037914 B-cell disorder Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 102000045108 human EGFR Human genes 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 description 1
- 101000727826 Homo sapiens Tyrosine-protein kinase RYK Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102000014842 Multidrug resistance proteins Human genes 0.000 description 1
- 108050005144 Multidrug resistance proteins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100027744 Semaphorin-4D Human genes 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 102100029759 Tyrosine-protein kinase RYK Human genes 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000006659 positive regulation of apoptotic process Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001119—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8487098P | 1998-05-08 | 1998-05-08 | |
US60/084,870 | 1998-05-08 | ||
PCT/US1999/010065 WO1999057981A1 (en) | 1998-05-08 | 1999-05-07 | Compositions and methods for active vaccination |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2002514573A true JP2002514573A (ja) | 2002-05-21 |
Family
ID=22187732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000547851A Abandoned JP2002514573A (ja) | 1998-05-08 | 1999-05-07 | 能動的なワクチン接種のための組成物および方法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1075184A4 (de) |
JP (1) | JP2002514573A (de) |
CA (1) | CA2330212A1 (de) |
WO (1) | WO1999057981A1 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006516258A (ja) * | 2002-12-27 | 2006-06-29 | シェンジェンシチンファユアンシンシェンウイヤオカジヨウシャンゴンシ | ワクチンおよび抗腫瘍ワクチンを調製する方法 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7198920B1 (en) | 1999-01-29 | 2007-04-03 | Corika Corporation | HER-2/neu fusion proteins |
IL152054A0 (en) | 2000-04-13 | 2003-05-29 | Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh | Vaccine against cancerous diseases which is based on mimotopes of antigens expressed on tumor cells |
US7229623B1 (en) | 2000-08-03 | 2007-06-12 | Corixa Corporation | Her-2/neu fusion proteins |
US6911204B2 (en) | 2000-08-11 | 2005-06-28 | Favrille, Inc. | Method and composition for altering a B cell mediated pathology |
WO2002014503A2 (en) * | 2000-08-14 | 2002-02-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies |
CU22979A1 (es) * | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
EP1236740B1 (de) * | 2001-02-28 | 2012-07-18 | Bio Life Science Forschungs- und Entwicklungsges.m.b.H. | Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind |
CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
FR2844514B1 (fr) * | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
US7812116B2 (en) * | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
US20060018911A1 (en) * | 2004-01-12 | 2006-01-26 | Dana Ault-Riche | Design of therapeutics and therapeutics |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5550214A (en) * | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
-
1999
- 1999-05-07 EP EP99921790A patent/EP1075184A4/de not_active Withdrawn
- 1999-05-07 WO PCT/US1999/010065 patent/WO1999057981A1/en not_active Application Discontinuation
- 1999-05-07 CA CA002330212A patent/CA2330212A1/en not_active Abandoned
- 1999-05-07 JP JP2000547851A patent/JP2002514573A/ja not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006516258A (ja) * | 2002-12-27 | 2006-06-29 | シェンジェンシチンファユアンシンシェンウイヤオカジヨウシャンゴンシ | ワクチンおよび抗腫瘍ワクチンを調製する方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1075184A1 (de) | 2001-02-14 |
CA2330212A1 (en) | 1999-11-18 |
WO1999057981A1 (en) | 1999-11-18 |
EP1075184A4 (de) | 2002-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8444974B2 (en) | Use of antibodies for the vaccination against cancer | |
Zhang et al. | Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases | |
JP3583420B2 (ja) | 二特異的試薬を用いた標的免疫化 | |
AU765822B2 (en) | CD40 binding molecules and CTL peptides for treating tumors | |
AU2006228067A1 (en) | Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells | |
JP2002518347A (ja) | 前立腺癌治療のための免疫療法組成物および方法 | |
Kitamura et al. | Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. | |
JP2002514573A (ja) | 能動的なワクチン接種のための組成物および方法 | |
JP2001517638A (ja) | 小細胞肺癌に対するフコーシルgm−1−klh接合体ワクチン | |
JP2013520482A (ja) | 癌ワクチン | |
JP2003514028A (ja) | ワクチンとしての抗体の新たな使用 | |
Hurvitz et al. | Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId™ | |
Kim et al. | Impact of minimal tumor burden on antibody response to vaccination | |
Carlring et al. | Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice | |
JP3847794B2 (ja) | 抗イディオタイプ抗体11d10を使用するhmfg関連腫瘍の発達を遅延させる方法 | |
US20080241177A1 (en) | Idiotypic vaccine | |
US20050169929A1 (en) | Use of a vaccine for active immunization against cancer | |
JP2984366B2 (ja) | 免疫抑制ムチンを生成する腺がんの能動的特異免疫療法 | |
JPH09509649A (ja) | 免疫化同種異系骨髄ドナーからの活性腫瘍特異的免疫化の移入のための方法および組成物 | |
CA2265670A1 (en) | Nucleosome-based anti-tumor compositions | |
Arlen et al. | Monoclonal antibodies and their role in modulation of the immune response | |
US20040265318A1 (en) | Use of antibodies for the vaccination against cancer | |
Lim et al. | Idiotypic Immune Targeting of Multiple Myeloma | |
AU2004213066A1 (en) | Idiotypic vaccine | |
KR20000011003A (ko) | 면역 반응을 개시시키기 위해 다중 에피토프 항원의 입체형태를변화시키기 위한 방법 및 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060508 |
|
A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20070910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070910 |